Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase

Holder, Sheldon L.; Zemskova, Marina; Zhang, Chao; Tabrizizad, M.; Bremer, Ryan; Neidigh, Jonathan W.; Lilly, Michael B.

doi:10.1158/1535-7163.mct-06-0397

Cited by 164 publications

(138 citation statements)

References 33 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…Indeed, small molecule inhibitors of the Pim-1 kinase have been recently described in vitro and in cell-based systems. [33][34][35] Targeting the Pim-1 kinase may be a beneficial addition to a traditional cancer chemotherapy regimen.…”

Section: Discussionmentioning

confidence: 99%

Pim-1 controls NF-κB signalling by stabilizing RelA/p65

et al. 2009

View full text Add to dashboard Cite

Post-translational modification and degradation of proteins by the ubiquitin-proteasome system are key regulatory mechanisms in cellular responses to various stimuli. The NF-jB signaling pathway is controlled by the ubiquitin-mediated proteolysis. RelA/p65, which is a main subunit of NF-jB, is ubiquitinated for degradation by SOCS-1, but the functional mechanism of its ubiquitination remains poorly understood. In this study we show that phosphorylation of RelA/p65 at Ser276 prevents its degradation by ubiquitin-mediated proteolysis. In contrast, impairment of Ser276 phosphorylation affects constitutive degradation of RelA/p65. Importantly, we identify Pim-1 as a further kinase responsible for the phosphorylation of RelA/p65 at Ser276. Depletion of Pim-1 hinders not only Ser276 phosphorylation but also transactivation of RelA/p65 target genes. We also show that Pim-1 contributes to recruitment of RelA/p65 to jB-elements to activate NF-jB signalling after TNF-a stimulation. In concert with these results, the knockdown of Pim-1 impairs IL-6 production and augments apoptosis by interfering RelA/p65 activation. These findings provide a model in which Pim-1 phosphorylation of RelA/p65 at Ser276 allows defense against ubiquitin-mediated degradation and whereby exerts activation of NF-jB signalling. NF-kB is an inducible transcription factor that controls the expression of a number of proteins involved in the regulation of cell survival and immune response. 1 It is a dimmer formed from a multisubset family consisting of RelA/p65, RelB, c-Rel, p105/p50 (NF-kB1), and p100/p52 (NF-kB2). It is activated by a bewildering array of stimuli and its activation is regulated by multiple distinct signalling cascades, including inhibitors of the NF-kB (IkB) kinase (IKK) signalosome. IKK phosphorylates IkB-a at Ser32 and Ser36 in response to a variety of stimuli, resulting in its ubiquitination and subsequent proteasomal degradation. The released NF-kB targets to the nucleus and thereby induces the expression of specific target genes. In addition to nuclear translocation of the NF-kB complex, previous studies have shown that a subunit of NF-kB, RelA/ p65, is post-translationally modified, such as phosphorylation, ubiquitination, or acetylation, and these changes influence its transcriptional activity. In particular, phosphorylation of RelA/ p65 at Ser276, Ser529, or Ser536 could be indispensable for its ability to function as an activator of gene expression. 2 However, recent findings showing a role for Ser529/536 phosphorylation on RelA/p65 activation in response to TNF-a arise conflicting evidences. [3][4][5] In contrast, accumulating evidences have revealed that Ser276 phosphorylation is critical for transactivation of RelA/p65 at least in response to TNF-a. Moreover, Ser276 is the major phosphorylation site of RelA/p65 induced by TNF-a. Phospho-RelA/p65 at Ser276 forms a stable complex with co-activator CBP/p300, a modification apparently required for assembly of a functional enhanceosome on the responsive promoters. 6,7 As nucle...

show abstract

Section: Discussionmentioning

confidence: 99%

Pim-1 controls NF-κB signalling by stabilizing RelA/p65

et al. 2009

View full text Add to dashboard Cite

show abstract

“…118,122 The second class of PIM inhibitors does not interact with the hinge region by forming classical hydrogen bonds and can therefore be considered as ATP competitive but not ATP mimetic inhibitors. This non-canonical binding mode has been first identified for pyrazolo [1,5-a]pyrimidines and the related imidazo[1,2-b]pyridazine (compound 4) and LY294002 (data not shown), initially described as a potent phosphatidylinositol 3-kinase inhibitor.…”

Section: -121mentioning

confidence: 99%

PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers

Brault¹,

Gasser²,

Bracher³

et al. 2010

Haematologica

327

413

View full text Add to dashboard Cite

The online version of this article has a Supplementary Appendix.The identification as cooperating targets of Proviral Integrations of Moloney virus in murine lymphomas suggested early on that PIM serine/threonine kinases play an important role in cancer biology. Whereas elevated levels of PIM1 and PIM2 were mostly found in hematologic malignancies and prostate cancer, increased PIM3 expression was observed in different solid tumors. PIM kinases are constitutively active and their activity supports in vitro and in vivo tumor cell growth and survival through modification of an increasing number of common as well as isoform-specific substrates including several cell cycle regulators and apoptosis mediators. PIM1 but not PIM2 seems also to mediate homing and migration of normal and malignant hematopoietic cells by regulating chemokine receptor surface expression. Knockdown experiments by RNA interference or dominant-negative acting mutants suggested that PIM kinases are important for maintenance of a transformed phenotype and therefore potential therapeutic targets. Determination of the protein structure facilitated identification of an increasing number of potent small molecule PIM kinase inhibitors with in vitro and in vivo anticancer activity. Ongoing efforts aim to identify isoform-specific PIM inhibitors that would not only help to dissect the kinase function but hopefully also provide targeted therapeutics. Here, we summarize the current knowledge about the role of PIM serine/threonine kinases for the pathogenesis and therapy of hematologic malignancies and solid cancers, and we highlight structural principles and recent progress on small molecule PIM kinase inhibitors that are on their way into first clinical trials. Haematologica 2010;95:1004-1015. doi:10.3324/haematol.2009 This is an open-access paper. ABSTRACTin blast crisis. 6 Abundant levels of PIM1 were found in hematopoietic cells. Moreover, sustained PIM1 expression was induced by cytokines that signal through structurally related receptors such as IL-3, GM-CSF, G-CSF or Subsequently, several studies have documented that PIM1 is a major downstream target of the signal transducer and activator of transcription (STATs) induced by a large variety of additional receptors such as IL-2, IL-7, IL-9, IFNγ, EPO, FLT3 or TPO.7 PIM1 expression is not only regulated at the transcriptional, but also at the posttranscriptional, translational and posttranslational levels ( Figure 1). Other studies have shown that PIM1 kinase is significantly protected from proteasomal degradation by heat shock proteins (Hsp70, Hsp90). 8,9 Moreover, it has been proposed that micro-RNAs, miR-1 and miR-210, might be implicated in regulation of PIM1 expression. 10,11 Germline inactivation of the PIM1 gene was associated with a mild phenotype as PIM1 deficient mice are ostensibly normal, healthy and fertile. However, subtle functional defects of the hematopoietic system have been identified: PIM1 -/-mice showed erythrocytic microcytosis and PIM1-/-B cells and bone marrow-derived mast c...

show abstract

“…These inhibitors display anticancer activity in prostate cancer cell lines, including those that are sensitive and resistant to chemotherapy (11). Despite the fact that the Pim-1 kinase inhibitors that have been investigated exhibit potential anticancer effects, there are a few small molecule inhibitors showing an inhibitory effect (25). In addition, other studies revealed that a Pim-1 specific monoclonal antibody markedly Table II.…”

Section: Discussionmentioning

confidence: 99%

Androgen deprivation therapy has no effect on Pim-1 expression in a mouse model of prostate cancer

Wang

Лі

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. The aim of the present study was to observe the dynamic changes of proto-oncogene, serine/threonine kinase, Pim-1 at the gene and protein level in a mouse model of prostate cancer following surgical castration. Using LNCaP cells to establish a subcutaneous xenograft model and orthotopic prostate cancer BALB/c nude mouse models, the xenograft models were divided into an androgen-dependent prostate cancer group (ADPC), an androgen deprivation therapy (ADT) group and an androgen independent prostate cancer (AIPC) group. Reverse transcription-polymerase chain reaction (RT-PCR), RT-quantitative PCR, ELISA and immunohistochemistry analyses were performed to compare the expression levels of Pim-1, prostate-specific antigen (PSA) and androgen receptor (AR) in tumor tissue of three subgroups. Agarose gel electrophoresis revealed that the RT-PCR results of the ADPC (0.59±0.01) and AIPC groups (1.14±0.015) were significantly different when compared with the ADT group (0.62±0.026; P<0.05). As for RT-qPCR, the ΔCq of Pim-1 in the ADPC (6.15±0.34) and AIPC (4.56±0.23) groups were significantly different compared with the ADT group (5.11±0.21; P<0.05). Using 2 -ΔΔCq as a relative quantification method to analyze the data, the amplification products of Pim-1 increased by 2.05 and 3.01 times in the ADT and AIPC groups, respectively. ELISA demonstrated the following: The serum concentration of PSA was 0 ng/ml in the control group, 0.48±0.025 ng/ml in the ADPC group and 0.87±0.023 ng/ml in the AIPC group, which were significantly different compared with the ADT group (0.17±0.032 ng/ml; P<0.01). Upon immunohistochemical staining, the protein expression levels of Pim-1 and AR, respectively, were 0.017±0.0021 and 0.032±0.009 in the ADPC group, 0.024±0.0019 and 0.040±0.011 in the AIPC group, and 0.018±0.0013 and 0.019±0.006 in the ADT group. The protein levels of Pim-1 and AR in the ADPC and AIPC groups were significantly different compared with the ADT group (P<0.01). In addition, an orthotopic prostate cancer animal model of ADT was successfully established in the current study, and further investigation revealed that ADT did not affect the expression of Pim-1 at the gene or protein levels; thus, it is hypothesized that Pim-1 may be important in the proliferation and differentiation of prostate cancer during ADT. IntroductionHuman proviral integration site for Moloney murine leukemia virus (Pim) is a proto-oncogene that was initially recognized 20 years ago (1); further studies have revealed that Pim encodes serine/threonine kinase and functions as a signaling regulator through cellular substrate phosphorylation (2,3). Pim participates in multiple biological functions, including numerous cellular signaling pathways, and regulates cell cycle progression, cell proliferation and differentiation, and inhibits apoptosis. Recently, the association between androgen receptor (AR) and the proto-oncogene, serine/threonine kinase, Pim-1, has been shown to be strong, and studies have indicated that Pim-1 is expressed in androgen-depen...

show abstract

Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase

Cited by 164 publications

References 33 publications

Pim-1 controls NF-κB signalling by stabilizing RelA/p65

Pim-1 controls NF-κB signalling by stabilizing RelA/p65

PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers

Androgen deprivation therapy has no effect on Pim-1 expression in a mouse model of prostate cancer

Contact Info

Product

Resources

About